Table 1.

Ongoing neoadjuvant trials with checkpoint inhibition in melanoma.

Trial	Design	N' of patients	Intervention	Pathologic complete response
Trials comparing adjuvant and neoadjuvant checkpoint inhibition
NCT02437279 (OpACIN)	Phase Ib	20	Arm A: Adjuvant ipi + nivo for 4 cycles	Arm A: N/A
			Arm B: Neoadjuvant ipi + nivo for 2 Cycles before surgery, and 2 after surgery	Arm B: 30%
Trials with only neoandjuvant arms
NCT02519322	Phase II	23	Arm A: Neoadjuvant nivo up to 4 cycles, adjuvant nivo up to 13 cycles	Arm A: 25%
			Arm B: Neoadjuvant ipi + nivo up to 3 cycles, adjuvant nivo up to 13 cycles	Arm B: 45%
NCT02434354	Phase I	29	200 mg of pembrolizumab, single cycle 3 weeks prior to	18,50%
			surgery then pembrolizumab q3w for a year following surgery
NCT02977052 (OpACIN-neo)	Phase II	86	Arm A: Neoadjuvant ipi (3 mg/kg) + nivo (1 mg/kg) for 2 cycles	Arm A: 47%
			Arm B: Neoadjuvant ipi (1 mg/kg) + nivo (3 mg/kg) for 2 cycles	Arm B: 57%
			Arm C: Neoadjuvant ipi (3 mg/kg) for 2 cycles followed by neoadjuvant nivo (3 mg/kg) for 2 cycles	Arm C: 23%
NCT02977052	Phase II	99	Neoadjuvant ipi + nivo for 6 weeks, target node resection, if pCR, no lymphadenectomy,	61% MPR
			if pPR, lymphadenectomy only, if no response, lymphadenectomy + adjuvant nivo for 52 weeks
Ipi, ipilimumab; MPR, major pathologic response, defined as < 10% viable tumor cells; nivo, nivolumab; pCR, pathologic complete response.
NCT02231775	Phase II	21	Arm A: Upfront surgery with consideration of adjuvant therapy	Arm A: NA
			Arm B: Neoadjuvant dabrafenib and trametinib for 8 weeks followed by adjuvant dabrafenib and trametinib for 44 weeks	Arm B: 50%
NCT01972347 (Neo Combi)	Phase II	35	Neoadjuvant dabrafenib and trametinib for 12 weeks, adjuvant therapy for 40 weeks	49%
Trials with only neoadjuvant arms
NTR4654	Phase II	20	Neoadjuvant dabrafenib and trametinib for 8 weeks in patients with unresectable disease followed by surgery if resectable	28.6%